article thumbnail

Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial

European Journal of Heart Failure

Baseline characteristics for the vericiguat global study in participants with chronic heart failure (VICTOR) trial. of participants had no prior hospitalization for heart failure. implantable cardioverter-defibrillators. The mean age of the participants was 6711years, 23.6% were women, 64.4% were White, and 10.7%

article thumbnail

Long-Term Outcomes of Resynchronization–Defibrillation for Heart Failure

The New England Journal of Medicine

Follow-up at a median of nearly 14 years showed a survival benefit for patients who received cardiac resynchronization with a defibrillator as compared with those who received a defibrillator alone.

article thumbnail

Lives Prolonged for Longtime CRT-D Users With Heart Failure

Med Page Today

(MedPage Today) -- Eligible heart failure patients with a wide QRS complex spent more time alive after use of a cardiac resynchronization therapy defibrillator (CRT-D) compared with an implantable cardioverter-defibrillator (ICD), according to.

article thumbnail

Cardiac resynchronization therapy via left bundle branch pacing in heart failure with complete left bundle branch block: is the defibrillator needed?

Frontiers in Cardiovascular Medicine

AimsThis retrospective cohort study aimed to investigate the efficacy of dual-chamber left Bundle branch pacing (LBBP) as an alternative therapy for heart failure patients with complete left bundle branch block (CLBBB) and indications for defibrillator with cardiac resynchronization therapy (CRT-D).Methods34

article thumbnail

Lasting benefits seen for cardiac resynchronization therapy with defibrillator

Medical Xpress - Cardiology

Receipt of a cardiac-resynchronization therapy-defibrillator (CRT-D) offers long term benefit for patients with heart failure, reduced ejection fraction, and a widened QRS complex, according to a study published in the Jan. 18 issue of the New England Journal of Medicine.

article thumbnail

Resynchronization–Defibrillation Sustains Long-Term Survival Benefit in Heart Failure

HCPLive

An analysis of the RAFT trial showed patients with heart failure treated with CRT-D experienced continued survival benefits during a median of nearly 14 years of follow-up.

article thumbnail

Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC)

European Journal of Heart Failure

Implantable devices form an integral part of the management of patients with heart failure (HF) and provide adjunctive therapies in addition to cornerstone drug treatment. Although the number of these devices is growing, only few are supported by robust evidence.